Search Results
Jan 12, 2026, 22:07 ET WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic
to provide GMP-compliant manufacturing on a global scale.DP5, WuXi Biologics' first commercial pre-filled syringe (PFS) manufacturing facility, delivers industry-leading PFS solutions to clients with production lines covering both clinical and commercial manufacturing. DPPC provides clients with
More news about: WuXi Biologics
Jan 12, 2026, 10:35 ET Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026
follows positive final results from the Company's VERSATILE-002 trial, which showed promising median overall survival and durable PFS, with the proposed amendment changing the PFS endpoint to a primary endpoint that can be evaluated earlier with significant statistical power.The amendment retains median
More news about: USA News Group
Jan 11, 2026, 12:00 ET IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference
free survival (PFS) data, from ongoing registrational Phase 2/3 OptimUM-02 trial of the darovasertib and crizotinib combination in first line (1L) patients with HLA*A2-negative metastatic UM (mUM) are expected in Q1 '26Randomized PFS analysis is based on the first 130 PFS events from
More news about: IDEAYA Biosciences, Inc.
Jan 10, 2026, 10:00 ET RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer
with disease progression, second-line options remain limited, with historical response rates of 32 to 36 percent and median progression-free survival (PFS) of 5.4 to 6.4 months using EGFR inhibitors and chemotherapy.5,6,7,8,9,10 Research has shown that MET alterations are a frequent cause
More news about: Johnson & Johnson
Jan 09, 2026, 16:00 ET Phanes Therapeutics Announces Positive Phase 2 Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline (1L) Treatment of Metastatic PDAC at ASCO GI 2026
partial response, with 1 patient pending confirmation).The median progression-free survival (mPFS) was 7.3 months with a 6-month PFS rate of 59%. The median overall survival (mOS) was 13.2 months and still maturing while 6-month OS rate was 93%. Responses were
More news about: Phanes Therapeutics, Inc.
Jan 08, 2026, 17:18 ET ARIS MINING EXPANDS HIGH-GRADE SEGOVIA RESERVE AND RESOURCE ESTIMATES
gold project, where a new Preliminary Economic Assessment has been completed and a Prefeasibility Study is in progress. Following completion of the PFS, Toroparu will be positioned to advance toward construction.Aris Mining also owns the Soto Norte gold project, where a Prefeasibility Study has
More news about: Aris Mining Corporation
Jan 08, 2026, 16:05 ET ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates
trial of ZYNLONTA in combination with rituximab in patients with 2L+ DLBCL once the pre-specified number of approximately 262 progression-free survival (PFS) events is reached and data are available. Publication of the full results is anticipated by the end of 2026. Assuming positive results, a supplemental
More news about: ADC Therapeutics SA
Jan 08, 2026, 10:30 ET VYLOY™ (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses
CLDN18.2-positive advanced gastric or GEJ cancer. In combination with chemotherapy, zolbetuximab demonstrated statistically significant improvements in PFS and OS compared with placebo plus chemotherapy in the SPOTLIGHT and GLOW Phase 3 clinical trials.2,3 In SPOTLIGHT and GLOW, the incidence
More news about: Astellas Pharma Inc.
Jan 08, 2026, 07:15 ET ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
runway into at least 2028 which assumes use of minimum liquidity amount required to be maintained under its loan agreement covenants; the timing of the PFS events and topline data release for LOTIS-5 and the results of the trial and full FDA approval; the Company's ability to grow ZYNLONTA® revenue
More news about: ADC Therapeutics SA
Jan 08, 2026, 07:00 ET Mayfair Delivers Robust Pre-Feasibility Study for the Fenn-Gib Gold Project
Pre-Feasibility Study ("PFS") for the Fenn-Gib gold project in the Timmins Gold District of Ontario, Canada. The study has been prepared in accordance with National Instrument 43-101 – Standards of Disclosure for Mineral Projects ("NI 43-101"). The NI 43-101 Technical Report for the PFS will be
More news about: Mayfair Gold Corp.
Jan 08, 2026, 06:15 ET Energy Fuels Announces Updated Feasibility Study for Toliara Rare Earth and HMS Project in Madagascar Confirming World-Class Scale and Economics, Including $1.8 Billion NPV and Ramping Up to Over $500 Million of Expected Annual EBITDA
and NI 43-101 (Canada), which consolidates and supersedes the 2021 definitive feasibility study (DFS) and 2024 monazite-focused prefeasibility study (PFS) prepared in compliance with JORC (Australia)."The FS confirms what we've known since we acquired the project in 2024. Vara Mada is
More news about: Energy Fuels Inc.
Jan 07, 2026, 10:32 ET How $594B in Precision Tech is Cracking the Metastatic Cancer Code
HR+/HER2- disease (3.7 months) and HER2-Low disease (3.9 months), with patients exhibiting a favorable Neutrophil-to-Lymphocyte Ratio achieving median PFS of 4.4 months versus 2.6 months in those with unfavorable NLR. "We are very excited to see the robust and positive biomarker data, which may enable
More news about: USA News Group
Jan 07, 2026, 07:37 ET First Mining Announces Socio-Economic Analysis for the Springpole Gold Project
included an analysis of the Project benefits. This analysis has been updated based on the recently announced updated Pre-Feasibility Study (the "PFS"). The Updated Analysis undertaken by WSP Canada Inc. demonstrates the major benefits to the local region around the Project, to Ontario and to Canada.
More news about: First Mining Gold Corp.
Jan 06, 2026, 21:50 ET Ivonescimab's Updated Label Shows Positive Dual Results in PFS and OS from HARMONi-A Study
P=0.019), with the survival benefit becoming more evident over time. It also reduced the risk of disease progression or death by 54% (PFS HR=0.46, P＜0.001), extending median PFS from 4.8 to 7.1 months.With a median follow-up of 32.5 months, the long-term safety profile of the ivonescimab combination
More news about: Akeso, Inc.
Jan 06, 2026, 13:32 ET Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival Benefit
significant and clinically meaningful prolongation of progression-free survival (PFS) with approximately 35% reduction in the risk of disease progression or death versus trastuzumab plus chemotherapy. This resulted in a median PFS of more than one year, representing a greater than four-month improvement compared
More news about: Jazz Pharmaceuticals plc
Jan 05, 2026, 04:27 ET Kelun-Biotech Announces Breakthrough Therapy Designation Granted in China for Sacituzumab Tirumotecan (sac-TMT) in Combination with Immunotherapy Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC
PD-L1-positive NSCLC, demonstrated a statistically significant and clinically meaningful improvement in its primary endpoint of progression-free survival (PFS). A positive trend was also observed in overall survival (OS). OptiTROP-Lung05 is the first Phase III study of an immunotherapy and ADC combination to
More news about: Kelun-Biotech
Jan 02, 2026, 16:05 ET ADC Therapeutics Announces New Employee Inducement Grant
runway into at least 2028 which assumes use of minimum liquidity amount required to be maintained under its loan agreement covenants; the timing of the PFS events and topline data release for LOTIS-5 and the results of the trial and full FDA approval; the Company's ability to grow ZYNLONTA® revenue
More news about: ADC Therapeutics SA
Dec 28, 2025, 21:24 ET Senhwa Biosciences Aims at Multi-Billion Dollar Global Market with CX-5461 Combined with ADC "Blockbuster" Therapy
1. CX-5461 RP2D combined with PD-1 inhibitor2. Safety & tolerability for CX-5461 monotherapy & combination3. PFS in refractory MSS CRC with liver metastases for CX-5461 monotherapy & combination
More news about: Senhwa Biosciences, Inc.
Dec 23, 2025, 07:00 ET First Mining Files Pre-Feasibility Study Technical Report for the Springpole Gold Project, Ontario, Canada
Mineral Projects ("NI 43-101") and has an effective date of December 1, 2025.The 2025 PFS results support a 30,000 tonnes-per-day ("tpd") open pit mining operation.2025 PFS Highlights1,2US$3.2 billion pre-tax net present
More news about: First Mining Gold Corp.
Dec 22, 2025, 07:00 ET Defense Metals Provides Joint Letter to Shareholders from Executive Chairman and CEO
well positioned to execute its long-term strategy.A major milestone in 2025 was the completion of the Pre-Feasibility Study (PFS) for the Wicheeda Project. The PFS confirmed the Wicheeda Project as the only undeveloped rare earth project in North America and Europe with proven mineral reserves,
More news about: Defense Metals Corp.
Dec 22, 2025, 03:00 ET Menarini Silicon Biosystems annuncia la pubblicazione dei risultati dello studio PACE, che mostrano il valore clinico della conta delle cellule tumorali circolanti con CELLSEARCH® in uno specifico sottotipo di carcinoma mammario metastatico
Sebbene nella popolazione complessiva non sia stata osservata alcuna differenza significativa nella sopravvivenza libera da progressione (PFS) tra i gruppi di trattamento, le pazienti con malattia aggressiva (5 o più CTC) hanno mostrato una riduzione clinicamente rilevante del rischio di progressione
More news about: Menarini Silicon Biosystems
Dec 17, 2025, 18:49 ET U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)
substitution mutations. The primary endpoint of the study is PFS (using RECIST v1.1 guidelines) as assessed by Blinded Independent Central Review (BICR). Secondary endpoints include OS, ORR, DoR, progression-free survival after first subsequent therapy (PFS2) and intracranial PFS.9Resistance
More news about: Johnson & Johnson
Dec 17, 2025, 18:33 ET INTEGRA DELIVERS ROBUST FEASIBILITY STUDY FOR DELAMAR GOLD-SILVER HEAP LEACH PROJECT HIGHLIGHTING IMPROVED ECONOMICS AND REDUCED DEVELOPMENT RISK
and processing: Two oxide heap leach facilities ("HLF") (vs. single large HLF design in the 2022 Pre-Feasibility Study ("PFS")), and two-stage crushing (vs. three-stage in PFS); reduced mine-site footprint and enhanced water usage strategy brings potential permitting advantages.Meaningful
More news about: Integra Resources Corp.
Dec 17, 2025, 06:30 ET Denison Announces Closing of Transaction with Skyharbour and Formation of Four Prospective Exploration Joint Ventures Proximal to Wheeler River
feasibility study was completed for the Phoenix deposit as an ISR mining operation, and an update to the previously prepared 2018 Pre-Feasibility Study ('PFS') was completed for Wheeler River's Gryphon deposit as a conventional underground mining operation. Based on the respective studies, both deposits have
More news about: Denison Mines Corp.
Dec 16, 2025, 16:01 ET Collective Mining Expands Ramp Zone by Drilling its Highest Grade Intercept Ever at Apollo: 24.80 Metres @ 29.42 g/t Gold Within 63.90 Metres @ 13.46 g/t Gold from 388.25 Metres
Lower Mine is derived from the NI 43-101 compliant technical report titled "Technical Report for the Marmato Gold Mine, Caldas Department, Colombia, PFS of the Lower Mine Expansion Project," with an effective date of June 30, 2022 (filed November 23, 2022). This report is available on Aris Mining Corporation's
More news about: Collective Mining Ltd.